53 results about "Pre-Therapy" patented technology

A medical digital expert system to predict a patient's response to a variety of treatments (using pre-treatment information) is described. The system utilizes data fusion, advanced signal / information processing and machine learning / inference methodologies and technologies to integrate and explore diverse sets of attributes, parameters and information that are available to select the optimal treatment choice for an individual or for a subset of individuals suffering from any illness or disease including psychiatric, mental or neurological disorders and illnesses. The methodology and system can also be used to determine or confirm medical diagnosis, estimate the level, index, severity or critical medical parameters of the illness or condition, or provide a list of likely diagnoses for an individual suffering / experiencing any illness, disorder or condition.

A medical system for ablating a tissue site with real-time monitoring during an electroporation treatment procedure. A pulse generator generates a pre-treatment (PT) test signal prior to the treatment procedure and intra-treatment (IT) test signals during the treatment procedure. A treatment control module determines impedance values from the PT test signal and IT test signals and determines a progress of electroporation and an end point of treatment in real-time based on the determined impedance values while the treatment progresses.

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.

A beam irradiation target verification apparatus (1) includes an X-ray switching emission process unit (6a) that causes a vertical X-ray emitting unit (13) to emit at least two types of X-rays using an energy-level switching unit (11), a vertical X-ray detection unit (14) that detects an X-ray emitted from the vertical X-ray emitting unit (13), a pre-therapy verification image generation process unit (7) that generates pre-therapy verification images (20B) and (20C) based on detection information on at least two types of X-rays obtained by the vertical X-ray detection unit (14), a reference image acquisition unit (3) that acquires a reference image (20A) obtained at a therapy planning stage, a comparison process unit (8a) that makes comparisons between the pre-therapy verification images (20B) and (20C) and the reference image (20A), and a result output unit (4) that outputs a comparison result obtained by the comparison process unit (8a). Thus, there is provided a beam irradiation target verification apparatus for therapeutic purposes capable of measuring internal conditions of a therapy patient and determining necessity of changing a therapy plan, easily and at a relatively low exposure level.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to determine the propensity of a patient to benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits an elevated pre-treatment expression level of one or more of CST7, NKG7, GZMH, MT-ND4, HLA-H, CCL5, CD8A, CMC1, CD8B, HCST, MT-CYB, MT-ND4L, KLRG1, MT-CO2, MT-ATP6, PLEK, CTSW, HLA-C, LYAR, LITAF, GZMB, KLRD1, FGFBP2, KLRC4-KLRK1, KLRK1, B2M, GZMA, ID2, CX3CR1, PRSS23, GNLY, PRF1, and PATL2. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.

An apparatus, method, system, computer-readable medium and use for individual patient therapy planning of diseases such as cancer for different therapy modalities, such as radiation therapy and chemotherapy is provided. A new aspect of the invention is that the degree of bone marrow depression of the patient is related to the count of immature blood platelets, which are measured before each treatment. Some embodiments of the invention provide an advantage allowing reducing the level of uncertainty in the prediction of the risk of bone marrow depression, and thus enabling to safely improve the therapy effect by an increase of the radiation dosage and / or chemical dosage to the individual patient while the risk for bone marrow depression is minimized.

A computer-implemented method evaluates a protocol for radiation therapy for a target volume of a patient. The method uses a computer system executing software instructions establishing computer processes. The computer processes receiving and storing data defining the protocol and characterizing the target volume. The computer processes parse the data to extract parameters characterizing the protocol. The computer processes apply the extracted parameters and the target volume to a model that represents relationships among sub-processes and variables pertinent to execution of the protocol in a patient. The computer processes obtain from the model an evaluation of the protocol and providing the evaluation as an output.

The invention discloses an adjuvant for high-intensity focusing and ultrasonic (HIFU) treatment, which can be used for lowering the EEF of the HIFU therapeutic target region for the patients, the adjuvant makes it possible to carry out HIFU treatment during deep layer tumor treatment without the requirement of ablation of the patients' rib. The invention also provides a method for increasing target region energy deposition and screening HIFU adjuvant in HIFU treatment.

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

The invention provides a molecular marker combination for pre-evaluating drug resistance in a prostatic cancer chemotherapy process. The molecular marker is formed by two prostatic cancer sensitive genes (a P53 gene and a GSTP1 gene) and a miRNA (a miRNA-155), and can be applied for evaluating the chemotherapy drug resistance. In addition, the invention further provides a primer group and a kit for the evaluation; and the invention further provides application of the above primer group and kit in a united discriminant equation of molecular marker expression quantity. Through evaluating the relative expression quantity of the gene, the drug resistance existing in the combined prostatic cancer treatment of docetaxel and prednisone can be evaluated better.

The present invention relates to use of soluble CD27 as a biomarker to predict the reponse to an immune checkpoint inhibitor treatment. Inventors have worked with two cohorts of patients and have identified a soluble marker, CD27, present in the plasma of patients with renal cell cancer whose pre-treatment concentrations predict the response to anti-PD-1 / PD- L1. This marker appears more as a predictive marker of response to anti-PD1 / PD-L1 treatment, than as a prognostic marker. Indeed, it is not associated with better survival in patients with metastatic renal cell cancer treated with an antiangiogenic agent. This marker is not correlated with conventional clinical markers of severity that classify patients with metastatic renal cancer.

The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and / or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and / or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Disclosed are surprising new methods and kits for identifying and treating patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and bavituximab combination therapies. The methods and kits are based on the surprising finding that defined ranges of pre-treatment blood concentrations of β2-glycoprotein 1 (β2GPI), particularly functional β2GPI, act as an indicator to accurately predict patients with better treatment outcomes.

The invention discloses a method for calculating and verifying the dose of post-loading radiotherapy rapidly. The DICOM file corresponding to the patient is exported from the treatment planning system and saved in a fixed folder; the fixed folder is scanned to read the DICOM file from the DICOM file. The required dose calculation information; obtain the radiation source parameters, establish the dose rate distribution table, determine the direction of the radiation source, and perform dose calculation; compare the calculated dose results with the dose results in the treatment planning system to obtain the deviation values ​​Dev and γ Verification results; after the comparison is completed, the deviation value Dev and γ verification results are saved to a fixed folder, and the DICOM files in the fixed folder are automatically deleted. The invention can perform dose verification before treatment, which is simple and fast, and improves accuracy and efficiency. The whole verification process only takes a few minutes, does not require too much human-computer interaction, and can be used in various after-installed radiotherapy planning systems. It improves the quality control and assurance of afterloading radiation therapy and is suitable for promotion.